PFIZER | BH.IMMUN&BIO | PFIZER/ BH.IMMUN&BIO |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 37.5 | -8.3 | - | View Chart |
P/BV | x | 5.9 | 1.6 | 360.5% | View Chart |
Dividend Yield | % | 1.7 | 0.0 | - |
PFIZER BH.IMMUN&BIO |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-23 |
BH.IMMUN&BIO Mar-23 |
PFIZER/ BH.IMMUN&BIO |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,662 | 52 | 9,000.7% | |
Low | Rs | 3,407 | 21 | 16,619.3% | |
Sales per share (Unadj.) | Rs | 530.0 | 10.3 | 5,130.2% | |
Earnings per share (Unadj.) | Rs | 136.4 | -3.9 | -3,539.2% | |
Cash flow per share (Unadj.) | Rs | 159.4 | -3.8 | -4,188.0% | |
Dividends per share (Unadj.) | Rs | 70.00 | 0 | - | |
Avg Dividend yield | % | 1.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 701.0 | 20.4 | 3,431.6% | |
Shares outstanding (eoy) | m | 45.75 | 43.18 | 106.0% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.6 | 3.5 | 217.5% | |
Avg P/E ratio | x | 29.6 | -9.4 | -315.3% | |
P/CF ratio (eoy) | x | 25.3 | -9.5 | -266.5% | |
Price / Book Value ratio | x | 5.8 | 1.8 | 325.2% | |
Dividend payout | % | 51.3 | 0 | - | |
Avg Mkt Cap | Rs m | 184,576 | 1,561 | 11,824.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 3,317 | 151 | 2,190.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 24,248 | 446 | 5,435.6% | |
Other income | Rs m | 1,011 | 11 | 9,533.0% | |
Total revenues | Rs m | 25,258 | 457 | 5,530.7% | |
Gross profit | Rs m | 8,420 | -161 | -5,239.6% | |
Depreciation | Rs m | 1,055 | 2 | 52,755.0% | |
Interest | Rs m | 135 | 71 | 190.9% | |
Profit before tax | Rs m | 8,240 | -223 | -3,700.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,001 | -56 | -3,554.5% | |
Profit after tax | Rs m | 6,239 | -166 | -3,749.8% | |
Gross profit margin | % | 34.7 | -36.0 | -96.4% | |
Effective tax rate | % | 24.3 | 25.3 | 96.1% | |
Net profit margin | % | 25.7 | -37.3 | -69.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,933 | 358 | 6,964.1% | |
Current liabilities | Rs m | 6,574 | 940 | 699.0% | |
Net working cap to sales | % | 75.7 | -130.6 | -58.0% | |
Current ratio | x | 3.8 | 0.4 | 996.3% | |
Inventory Days | Days | 93 | 85 | 109.4% | |
Debtors Days | Days | 2 | 1,135 | 0.2% | |
Net fixed assets | Rs m | 13,780 | 1,262 | 1,092.0% | |
Share capital | Rs m | 458 | 432 | 106.0% | |
"Free" reserves | Rs m | 31,616 | 450 | 7,020.4% | |
Net worth | Rs m | 32,073 | 882 | 3,635.8% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 39,031 | 1,620 | 2,409.4% | |
Interest coverage | x | 62.1 | -2.2 | -2,884.2% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.3 | 225.6% | |
Return on assets | % | 16.3 | -5.9 | -276.2% | |
Return on equity | % | 19.5 | -18.9 | -103.1% | |
Return on capital | % | 26.1 | -17.2 | -151.5% | |
Exports to sales | % | 2.8 | 0 | - | |
Imports to sales | % | 0 | 14.5 | 0.2% | |
Exports (fob) | Rs m | 688 | NA | - | |
Imports (cif) | Rs m | 8 | 65 | 13.0% | |
Fx inflow | Rs m | 688 | 0 | - | |
Fx outflow | Rs m | 8 | 65 | 13.0% | |
Net fx | Rs m | 679 | -65 | -1,053.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,557 | 109 | 3,265.5% | |
From Investments | Rs m | -361 | 5 | -7,803.0% | |
From Financial Activity | Rs m | -3,458 | -147 | 2,350.4% | |
Net Cashflow | Rs m | -262 | -34 | 779.3% |
Indian Promoters | % | 0.0 | 59.3 | - | |
Foreign collaborators | % | 63.9 | 0.0 | - | |
Indian inst/Mut Fund | % | 18.7 | 0.0 | - | |
FIIs | % | 3.3 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 36.1 | 40.8 | 88.5% | |
Shareholders | 109,214 | 35,313 | 309.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PFIZER With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Pfizer | BH.IMMUN&BIO | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.59% | 12.46% | 1.03% |
1-Month | -3.50% | 9.97% | 1.10% |
1-Year | 9.02% | 37.99% | 53.75% |
3-Year CAGR | -7.14% | -8.02% | 14.67% |
5-Year CAGR | 5.51% | 31.91% | 19.26% |
* Compound Annual Growth Rate
Here are more details on the Pfizer share price and the BH.IMMUN&BIO share price.
Moving on to shareholding structures...
The promoters of Pfizer hold a 63.9% stake in the company. In case of BH.IMMUN&BIO the stake stands at 59.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Pfizer and the shareholding pattern of BH.IMMUN&BIO.
Finally, a word on dividends...
In the most recent financial year, Pfizer paid a dividend of Rs 70.0 per share. This amounted to a Dividend Payout ratio of 51.3%.
BH.IMMUN&BIO paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Pfizer, and the dividend history of BH.IMMUN&BIO.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.